Skip to main content

Advertisement

SpringerLink
Log in

Therapy for fungal infections in leukemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Invasive fungal infections remain a common cause of morbidity and mortality among patients with leukemia who become further compromised by neutropenia. Candida and Aspergillus spp account for the vast majority of these infections, but other, less commonly recognized fungi can cause life-threatening infection in these hosts as well. The earlier, more limited antifungal armamentarium of ketoconazole, flucytosine, and amphotericin B has been substantially augmented by the availability of fluconazole, itraconazole, and the lipid-associated amphotericin formulations. Intense clinical study has focused on the use of these agents in empiric treatment, treatment of suspected or proven infection, and prophylaxis. Recognition of the limitations of antifungal therapy in the neutropenic host has led to evaluation of the adjunctive role of immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Warnock DW: Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother 1998, 41(suppl D):95–105.

    Article  PubMed  CAS  Google Scholar 

  2. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ: The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998, 26:1270–1278.

    PubMed  CAS  Google Scholar 

  3. Guiot HF, Fibbe WE, Van’t Wout JW: Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994, 18:525–532.

    PubMed  CAS  Google Scholar 

  4. Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115–125.

    PubMed  CAS  Google Scholar 

  5. Iwen PC, Kelly DM, Reed EC, Hinrichs SH: Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995, 20:342–347.

    PubMed  CAS  Google Scholar 

  6. Sallah S: Hepatosplenic candidiasis in patients with acute leukemia: increasingly encountered complication. Anticancer Res 1999, 19:757–760.

    PubMed  CAS  Google Scholar 

  7. Anttila VJ, Ruutu P, Bondestram S, et al.: Hepatosplenic yeast infection in patients with acute leukemia: a diagnostic problem. Clin Infect Dis 1994, 18:979–81.

    PubMed  CAS  Google Scholar 

  8. Karthaus M, Huebner G, Geissler RG, et al.: Hepatic lesions of chronic disseminated systemic candidiasis in leukemia patients may become visible during neutropenia: value of serial ultrasound examinations. Blood 1998, 91:3087–3089.

    PubMed  CAS  Google Scholar 

  9. Caillot D, Casasnovas O, Bernard A, et al.: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15:139–147.

    PubMed  CAS  Google Scholar 

  10. Nalesnick MA, Myerowitz RL, Jenkins R, et al.: Significance of Aspergillus species isolated from respiratory secretions in the diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 1980, 11:370–376.

    Google Scholar 

  11. Kahn FW, Jones JM, England DM: The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis. Am J Clin Pathol 1986, 86:518–523.

    PubMed  CAS  Google Scholar 

  12. Jones ME, Fox AJ, Barnes AJ, et al.: PCR-ELISA for the early diagnosis of invasive pulmonary Aspergillus infection in neutropenic patients. J Clin Pathol 1998, 51:652–656.

    Article  PubMed  CAS  Google Scholar 

  13. Krcmery V, Krupova I, Denning DW: Invasive yeast infections other than Candida spp in acute leukemia. J Hosp Infect 1999, 41:181–194.

    Article  PubMed  CAS  Google Scholar 

  14. Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA: Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995, 76:2357–2362.

    Article  PubMed  CAS  Google Scholar 

  15. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996, 23:608–615.

    PubMed  CAS  Google Scholar 

  16. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998, 27:603–618.

    PubMed  CAS  Google Scholar 

  17. Anaissie EJ, White MH, Uzon O, et al.: Amphotericin B lipid complex vs amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial. Proceedings of Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995(330).

  18. White MH, Anaissie EJ, Kusne S, et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997, 24:635–642.

    PubMed  CAS  Google Scholar 

  19. Anaissie E, Bodey G, Kantarjian H, et al.: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991, 91:142–150.

    Article  PubMed  CAS  Google Scholar 

  20. Flannery MT, Simmons DB, Saba H, et al.: Fluconazole in the treatment of hepatosplenic candidiasis. Arch Intern Med 1992, 152:406–408.

    Article  PubMed  CAS  Google Scholar 

  21. Denning DW, Lee JY, Hostetler JS, et al.: NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994, 97:135–144.

    Article  PubMed  CAS  Google Scholar 

  22. Graybill JR: Itraconazole: managing mycotic complications in immunocompromised patients. Semin Oncol 1998, 25:58–63.

    PubMed  CAS  Google Scholar 

  23. Sabo JA, Abdel-Rahman SM: Voriconazole: a new triazole antifungal. Ann Pharmacother 2000, 34:1032–1043.

    Article  PubMed  CAS  Google Scholar 

  24. Winston DJ, Hawthorn JW, Schuster MG, et al.: A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000, 108:282–289. A randomized trial demonstrating that fluconazole can be an effective and safe alternative to amphotericin, with certain caveats.

    Article  PubMed  CAS  Google Scholar 

  25. Malik IA, Moid I, Aziz Z, et al.: A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998, 105:478–483.

    Article  PubMed  CAS  Google Scholar 

  26. Walsh TJ, Finberg RW, Arndt C, et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999, 340:764–771. This randomized, double-blind trial clearly demonstrates the equal effectiveness of liposomal amphotericin for empiric treatment of fever and neutropenia.

    Article  PubMed  CAS  Google Scholar 

  27. White MH, Bowden RA, Sandler ES, et al.: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998, 27:296–302.

    PubMed  CAS  Google Scholar 

  28. Slavin MA, Osborne B, Adams R, et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995, 171:1545–1552.

    PubMed  CAS  Google Scholar 

  29. Schaffner A, Schaffner M: Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995, 172:1035–1041.

    PubMed  CAS  Google Scholar 

  30. Winston DJ, Chandrasekar PH, Lazarus HM, et al.: Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, doubleblind, multicenter trial. Ann Intern Med 1993, 118:495–503.

    PubMed  CAS  Google Scholar 

  31. Rotstein C, Bow EJ, Laverdiere M, et al.: Randomized placebocontrolled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999, 28:331–340. This completed randomized, placebo-controlled trial demonstrates the efficacy of fluconazole prophylaxis for patients with neutropenic cancer.

    PubMed  CAS  Google Scholar 

  32. Wingard JR, Merz WG, Rinaldi MG, et al.: Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993, 37:1847–1849.

    PubMed  CAS  Google Scholar 

  33. Menichetti F, Del Favero A, Martino P, et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999, 28:250–255.

    PubMed  CAS  Google Scholar 

  34. Tricot G, Joosten E, Boogaerts MA, et al.: Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987, 9:S94-S99.

    PubMed  Google Scholar 

  35. Prentice AG, Warnock DW, Johnson SAN, et al.: Multiple dose pharmacokinetics of an oral solution of itraconazole in autologus bone marrow transplant recipients. J Antimicrob Chemother 1994, 34:247–252.

    Article  PubMed  CAS  Google Scholar 

  36. Prentice AG, Warnock DW, Johnson SAN, et al.: Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukemia. J Antimicrob Chemother 1995, 36:657–663.

    Article  PubMed  CAS  Google Scholar 

  37. Bow EJ, Loewen R, Cheang MS, et al.: Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenic role of the antileukemic regimen. Clin Infect Dis 1995, 21:361–369.

    PubMed  CAS  Google Scholar 

  38. Djeu J: Modulators of immune response to fungi. In Fungal Infections and Immune Responses. Edited by Murphy JW, Friedman H, Bendinelli M. New York: Plenum Press; 1993:521–532.

    Google Scholar 

  39. Maher DW, Lieschke GJ, Green M, et al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia: a doubleblind, placebo-controlled trial. Ann Intern Med 1994, 121:492–501.

    PubMed  CAS  Google Scholar 

  40. Rodriguez LJ, Grazziutti ML, Rex JH, Anaissie EJ: The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998, 26:1270–1278. This article discusses in detail the potential role of cytokine therapy as treatment for fungal disease, reviewing the most recent studies on the subject.

    Google Scholar 

  41. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S: Role of granulocyte macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993, 17:705–707.

    PubMed  CAS  Google Scholar 

  42. Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al.: Long term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant macrophage colony-stimulating factor. Blood 1993, 82:1422–1427.

    PubMed  CAS  Google Scholar 

  43. Spielberger RT, Falleroni MJ, Coene AJ, Larson RA: Comcomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. Clin Infect Dis 1993, 16:528–530.

    PubMed  CAS  Google Scholar 

  44. Grauer ME, Bokemeyer C, Bautsch W, et al.: Successful treatment of a Trichosporon beigelli septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor. Infection 1994, 22:283–286.

    Article  PubMed  CAS  Google Scholar 

  45. Stevens DA: Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998, 26:1266–1269. A comprehensive and up-to-date review of innovations for combination immunotherapy and chemotherapy as treatment for fungal infections.

    PubMed  CAS  Google Scholar 

  46. Fleming R, Anaissie E, O’Brien S, et al.: Treatment of neutropenia related fungal infections with G-CSF mobilized granulocytes transfusions [abstract]. American Society for Hematology, December 7–10, 1996, New York, NY (1312).

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Montefiore Medical Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, 10461, Bronx, NY, USA

    Robert E. Segal MD & Grace Y. Minamoto MD

Authors
  1. Robert E. Segal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grace Y. Minamoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Segal, R.E., Minamoto, G.Y. Therapy for fungal infections in leukemia. Curr Oncol Rep 3, 201–208 (2001). https://doi.org/10.1007/s11912-001-0051-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-001-0051-2

Keywords

Search

Navigation